FSH and Estrogen Levels Are NOT Accurate When Checked on Depo-Provera
Serum FSH and estradiol levels should not be checked while a patient is actively taking Depo-Provera (depot medroxyprogesterone acetate, DMPA), as this medication significantly suppresses and distorts these hormone levels, rendering them unreliable for clinical decision-making. If hormone assessment is necessary, DMPA must be discontinued for at least 3 months before obtaining accurate measurements 1.
Why DMPA Interferes with Hormone Testing
Depo-Provera acts as a "macro-progestin with antigonadotropic action" 1. This means it:
- Suppresses gonadotropin secretion (FSH and LH) by inhibiting the hypothalamic-pituitary-ovarian axis 2
- Reduces serum estrogen levels significantly 2
- Creates an artificial hormonal milieu that does not reflect the patient's true ovarian function
The 2021 European guidelines on premature ovarian insufficiency explicitly state that FSH levels will be "underestimated, often strongly" in women taking macro-progestins like DMPA, and that antigonadotropic treatment must be withdrawn for a second assay at least 3 months later 1.
Clinical Implications and Practical Approach
If You Need to Assess Menopausal Status or Ovarian Function:
Discontinue DMPA and wait at least 3 months before checking FSH and estradiol levels 1
Do NOT interrupt DMPA just to check FSH if the patient is satisfied with the method and doesn't need the information urgently 3, 4
If checking FSH in women ≥50 years old who have been on DMPA long-term:
- Research shows elevated FSH can sometimes be detected even during DMPA use 3, 4
- However, 40.6% of women with one elevated FSH had normal FSH on subsequent testing 3
- At least two consecutive elevated FSH measurements (>25-35 IU/L) are needed to confirm menopausal status 3
- Even then, results remain less reliable than in non-users
Important Caveats:
The American Association of Clinical Endocrinologists explicitly states that FSH levels cannot be used to monitor adequacy of estrogen replacement (similar principle applies here), as estrogen is not the only regulator of FSH—inhibin also plays a role 5. This underscores why hormone levels during exogenous hormone use are inherently unreliable.
DMPA's mechanism of action involves inhibiting follicular maturation and ovulation while thickening cervical mucus 2. The medication creates profound gonadotropin suppression—studies show LH can be suppressed to <0.4% of baseline and FSH to 1-5% of baseline 6, 7.
Alternative Approaches
If you're trying to determine menopausal status in a DMPA user:
- Clinical assessment is more reliable: evaluate symptoms (vasomotor flushes, night sweats, vaginal atrophy) 1
- Consider age: Women ≥50 years have higher probability of being postmenopausal 3
- AMH (anti-Müllerian hormone) may provide additional information about ovarian reserve, though interpretation requires caution in women <25 years 8
- If contraception is no longer needed, simply discontinue DMPA and reassess after 3+ months
Bottom Line
Do not rely on FSH or estradiol measurements obtained while a patient is taking Depo-Provera. The antigonadotropic effects of DMPA fundamentally alter the hypothalamic-pituitary-ovarian axis, making these values uninterpretable for assessing true ovarian function or menopausal status. If hormone assessment is clinically necessary, discontinue DMPA for at least 3 months first, or use clinical criteria and alternative markers instead.